 Bradley Dixon
Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atypical Hemolytic Uremic Syndrome | 8 | 2024 | 21 | 2.150 |
Why?
| | Glomerulonephritis, Membranoproliferative | 5 | 2026 | 25 | 1.790 |
Why?
| | Complement C3 | 4 | 2026 | 187 | 1.350 |
Why?
| | Kidney Diseases | 6 | 2025 | 426 | 1.200 |
Why?
| | Thrombotic Microangiopathies | 6 | 2020 | 19 | 1.060 |
Why?
| | Renal Insufficiency, Chronic | 6 | 2026 | 668 | 0.810 |
Why?
| | Complement Inactivating Agents | 5 | 2026 | 74 | 0.730 |
Why?
| | Antibodies, Monoclonal, Humanized | 9 | 2024 | 992 | 0.690 |
Why?
| | Tuberous Sclerosis | 4 | 2017 | 56 | 0.620 |
Why?
| | TRPM Cation Channels | 2 | 2019 | 73 | 0.610 |
Why?
| | Proteinuria | 5 | 2026 | 104 | 0.610 |
Why?
| | Hypertension | 5 | 2026 | 1276 | 0.590 |
Why?
| | Hemolytic-Uremic Syndrome | 1 | 2019 | 15 | 0.580 |
Why?
| | Nephrotic Syndrome | 3 | 2025 | 43 | 0.570 |
Why?
| | Kidney | 10 | 2025 | 1496 | 0.570 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2019 | 699 | 0.570 |
Why?
| | Lupus Nephritis | 3 | 2025 | 67 | 0.570 |
Why?
| | Complement System Proteins | 5 | 2025 | 314 | 0.530 |
Why?
| | Antihypertensive Agents | 3 | 2026 | 521 | 0.520 |
Why?
| | Acute Kidney Injury | 5 | 2025 | 874 | 0.520 |
Why?
| | Osmoregulation | 1 | 2017 | 4 | 0.510 |
Why?
| | DNA Damage | 2 | 2011 | 437 | 0.510 |
Why?
| | Kidney Tubules, Collecting | 1 | 2017 | 27 | 0.500 |
Why?
| | Osmotic Pressure | 1 | 2017 | 41 | 0.500 |
Why?
| | Immunosuppressive Agents | 6 | 2025 | 838 | 0.480 |
Why?
| | Autoimmunity | 1 | 2020 | 933 | 0.410 |
Why?
| | Peptides, Cyclic | 2 | 2026 | 273 | 0.410 |
Why?
| | Autoantibodies | 2 | 2020 | 1509 | 0.390 |
Why?
| | Epithelial Cells | 2 | 2019 | 1134 | 0.340 |
Why?
| | Cell Line | 3 | 2019 | 2823 | 0.330 |
Why?
| | Urothelium | 1 | 2011 | 33 | 0.330 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2026 | 115 | 0.320 |
Why?
| | Kidney Transplantation | 4 | 2024 | 712 | 0.290 |
Why?
| | Osmolar Concentration | 1 | 2009 | 168 | 0.290 |
Why?
| | Child | 25 | 2026 | 22739 | 0.290 |
Why?
| | Humans | 47 | 2026 | 145763 | 0.280 |
Why?
| | Glomerular Filtration Rate | 4 | 2026 | 765 | 0.280 |
Why?
| | Pyrimidines | 3 | 2022 | 530 | 0.280 |
Why?
| | RecQ Helicases | 1 | 2008 | 9 | 0.280 |
Why?
| | Angiomyolipoma | 3 | 2014 | 21 | 0.280 |
Why?
| | Cell Cycle | 1 | 2011 | 598 | 0.260 |
Why?
| | Complement Activation | 3 | 2025 | 399 | 0.250 |
Why?
| | Purines | 1 | 2008 | 187 | 0.250 |
Why?
| | Adolescent | 17 | 2026 | 22573 | 0.250 |
Why?
| | Urinary Bladder | 1 | 2009 | 196 | 0.250 |
Why?
| | Treatment Outcome | 11 | 2026 | 11793 | 0.240 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2026 | 229 | 0.240 |
Why?
| | Escherichia coli Proteins | 1 | 2008 | 201 | 0.240 |
Why?
| | Benzoates | 1 | 2026 | 51 | 0.240 |
Why?
| | Nephrology | 2 | 2024 | 60 | 0.230 |
Why?
| | Induction Chemotherapy | 1 | 2025 | 88 | 0.220 |
Why?
| | Prenatal Injuries | 1 | 2005 | 1 | 0.220 |
Why?
| | Hypertension, Renal | 1 | 2005 | 15 | 0.220 |
Why?
| | Calcium Channel Blockers | 1 | 2026 | 166 | 0.220 |
Why?
| | Retroperitoneal Space | 1 | 2005 | 18 | 0.220 |
Why?
| | Nephrocalcinosis | 1 | 2024 | 12 | 0.220 |
Why?
| | Familial Hypophosphatemic Rickets | 1 | 2024 | 6 | 0.220 |
Why?
| | Hematoma | 1 | 2005 | 63 | 0.210 |
Why?
| | Piperidines | 1 | 2026 | 222 | 0.210 |
Why?
| | Kidney Diseases, Cystic | 2 | 2017 | 24 | 0.210 |
Why?
| | Rituximab | 1 | 2025 | 210 | 0.210 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2024 | 41 | 0.210 |
Why?
| | Polycystic Kidney Diseases | 1 | 2005 | 71 | 0.210 |
Why?
| | Cost of Illness | 1 | 2026 | 324 | 0.200 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2017 | 29 | 0.200 |
Why?
| | Kidney Neoplasms | 3 | 2014 | 414 | 0.200 |
Why?
| | Disease Management | 2 | 2020 | 653 | 0.200 |
Why?
| | Nephritis | 1 | 2023 | 22 | 0.190 |
Why?
| | Slipped Capital Femoral Epiphyses | 1 | 2022 | 7 | 0.190 |
Why?
| | Femur Head Necrosis | 1 | 2022 | 15 | 0.190 |
Why?
| | Delphi Technique | 1 | 2024 | 333 | 0.180 |
Why?
| | Terminology as Topic | 1 | 2024 | 259 | 0.180 |
Why?
| | Complement Factor B | 1 | 2023 | 106 | 0.180 |
Why?
| | Indoles | 1 | 2026 | 507 | 0.180 |
Why?
| | Self-Management | 1 | 2025 | 204 | 0.180 |
Why?
| | Pharmacists | 1 | 2025 | 258 | 0.180 |
Why?
| | Arthritis, Juvenile | 1 | 2022 | 60 | 0.180 |
Why?
| | Male | 21 | 2026 | 73003 | 0.180 |
Why?
| | Female | 22 | 2026 | 79035 | 0.170 |
Why?
| | DNA | 1 | 2008 | 1437 | 0.170 |
Why?
| | Wounds, Nonpenetrating | 1 | 2005 | 321 | 0.170 |
Why?
| | Rheumatology | 1 | 2022 | 133 | 0.170 |
Why?
| | Child, Preschool | 11 | 2026 | 11868 | 0.170 |
Why?
| | Recurrence | 1 | 2024 | 1139 | 0.160 |
Why?
| | Glomerulonephritis | 1 | 2019 | 44 | 0.150 |
Why?
| | Risk Factors | 5 | 2025 | 10917 | 0.150 |
Why?
| | Tumor Suppressor Proteins | 2 | 2012 | 322 | 0.140 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 238 | 0.140 |
Why?
| | Plasma Exchange | 1 | 2019 | 18 | 0.140 |
Why?
| | Cilia | 2 | 2019 | 172 | 0.140 |
Why?
| | Mice, Transgenic | 2 | 2017 | 2191 | 0.140 |
Why?
| | Hirschsprung Disease | 1 | 2020 | 92 | 0.140 |
Why?
| | Renal Dialysis | 2 | 2022 | 466 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2020 | 344 | 0.140 |
Why?
| | TRPP Cation Channels | 1 | 2019 | 74 | 0.140 |
Why?
| | Plasmapheresis | 1 | 2018 | 24 | 0.140 |
Why?
| | Critical Illness | 2 | 2023 | 900 | 0.140 |
Why?
| | Electronic Health Records | 3 | 2023 | 1202 | 0.140 |
Why?
| | Renal Replacement Therapy | 1 | 2019 | 100 | 0.140 |
Why?
| | Escherichia coli Infections | 1 | 2019 | 125 | 0.140 |
Why?
| | Sirolimus | 2 | 2017 | 282 | 0.130 |
Why?
| | Creatinine | 3 | 2026 | 515 | 0.130 |
Why?
| | Fluid Therapy | 1 | 2019 | 155 | 0.130 |
Why?
| | Blood Component Transfusion | 1 | 2018 | 102 | 0.130 |
Why?
| | Hydroxyprostaglandin Dehydrogenases | 1 | 2017 | 3 | 0.130 |
Why?
| | GABA Plasma Membrane Transport Proteins | 1 | 2017 | 7 | 0.130 |
Why?
| | Caregivers | 2 | 2026 | 1074 | 0.130 |
Why?
| | Transfection | 2 | 2017 | 927 | 0.130 |
Why?
| | Saline Solution, Hypertonic | 1 | 2017 | 43 | 0.120 |
Why?
| | TRPV Cation Channels | 1 | 2017 | 43 | 0.120 |
Why?
| | Erythrocyte Transfusion | 1 | 2019 | 225 | 0.120 |
Why?
| | Quality of Life | 2 | 2026 | 3210 | 0.120 |
Why?
| | Plasma | 1 | 2018 | 223 | 0.120 |
Why?
| | Streptococcal Infections | 1 | 2019 | 171 | 0.120 |
Why?
| | Autoimmune Diseases | 1 | 2020 | 469 | 0.120 |
Why?
| | Gene Editing | 1 | 2017 | 89 | 0.120 |
Why?
| | Infant | 7 | 2025 | 10090 | 0.110 |
Why?
| | CRISPR-Cas Systems | 1 | 2017 | 166 | 0.110 |
Why?
| | Patient Selection | 1 | 2019 | 739 | 0.110 |
Why?
| | Cytomegalovirus Infections | 1 | 2017 | 206 | 0.110 |
Why?
| | Young Adult | 7 | 2026 | 14251 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1512 | 0.110 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 191 | 0.100 |
Why?
| | Pericytes | 1 | 2014 | 42 | 0.100 |
Why?
| | Complement Membrane Attack Complex | 1 | 2013 | 38 | 0.100 |
Why?
| | Retrospective Studies | 7 | 2025 | 17325 | 0.100 |
Why?
| | Adult | 7 | 2026 | 40872 | 0.100 |
Why?
| | Complement Factor D | 2 | 2022 | 28 | 0.090 |
Why?
| | Transplantation, Autologous | 2 | 2013 | 301 | 0.090 |
Why?
| | Complement Pathway, Alternative | 1 | 2013 | 121 | 0.090 |
Why?
| | Indazoles | 2 | 2022 | 85 | 0.090 |
Why?
| | Proline | 2 | 2022 | 82 | 0.090 |
Why?
| | Aminopyridines | 2 | 2022 | 129 | 0.090 |
Why?
| | Hematologic Neoplasms | 1 | 2013 | 168 | 0.090 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2012 | 118 | 0.090 |
Why?
| | Antigens, Polyomavirus Transforming | 1 | 2011 | 15 | 0.080 |
Why?
| | Biomarkers | 4 | 2025 | 4302 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2026 | 2064 | 0.080 |
Why?
| | Nephrolithiasis | 1 | 2010 | 10 | 0.080 |
Why?
| | Histoplasmosis | 1 | 2010 | 15 | 0.080 |
Why?
| | Prognosis | 1 | 2019 | 4329 | 0.080 |
Why?
| | Biopsy | 2 | 2025 | 1082 | 0.070 |
Why?
| | Mice | 3 | 2019 | 18355 | 0.070 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2009 | 55 | 0.070 |
Why?
| | Organ Specificity | 1 | 2009 | 309 | 0.070 |
Why?
| | Kanamycin Resistance | 1 | 2008 | 2 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2014 | 3551 | 0.070 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2008 | 27 | 0.070 |
Why?
| | Mutation | 2 | 2010 | 4090 | 0.070 |
Why?
| | Prospective Studies | 4 | 2023 | 8075 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 956 | 0.070 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2011 | 258 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2010 | 172 | 0.070 |
Why?
| | Incidence | 1 | 2014 | 2933 | 0.070 |
Why?
| | Stomach Neoplasms | 1 | 2009 | 128 | 0.070 |
Why?
| | Blood Pressure | 2 | 2025 | 1782 | 0.060 |
Why?
| | United States | 4 | 2025 | 16123 | 0.060 |
Why?
| | Stress, Mechanical | 1 | 2009 | 494 | 0.060 |
Why?
| | Plasmids | 1 | 2008 | 373 | 0.060 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 258 | 0.060 |
Why?
| | DNA Repair | 1 | 2009 | 255 | 0.060 |
Why?
| | DNA, Bacterial | 1 | 2008 | 320 | 0.060 |
Why?
| | DNA Replication | 1 | 2008 | 249 | 0.060 |
Why?
| | Signal Transduction | 2 | 2017 | 5223 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5992 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1184 | 0.060 |
Why?
| | Antigens, CD20 | 1 | 2025 | 34 | 0.060 |
Why?
| | Disease Progression | 2 | 2023 | 2865 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 119 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2025 | 272 | 0.050 |
Why?
| | Kidney Glomerulus | 1 | 2025 | 125 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2025 | 116 | 0.050 |
Why?
| | Nucleic Acid Conformation | 1 | 2008 | 723 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2026 | 169 | 0.050 |
Why?
| | Repressor Proteins | 1 | 2008 | 429 | 0.050 |
Why?
| | Apoptosis | 2 | 2012 | 2443 | 0.050 |
Why?
| | Animals | 3 | 2019 | 38097 | 0.050 |
Why?
| | Escherichia coli | 1 | 2008 | 835 | 0.050 |
Why?
| | Remission Induction | 1 | 2024 | 306 | 0.050 |
Why?
| | Algorithms | 2 | 2021 | 1850 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2025 | 484 | 0.050 |
Why?
| | Consensus | 1 | 2024 | 479 | 0.050 |
Why?
| | Middle Aged | 4 | 2025 | 36302 | 0.050 |
Why?
| | Atrophy | 1 | 2022 | 199 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2023 | 214 | 0.040 |
Why?
| | Graft Survival | 1 | 2024 | 519 | 0.040 |
Why?
| | Complement C5 | 1 | 2020 | 33 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 2123 | 0.040 |
Why?
| | Radiography | 1 | 2022 | 853 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 561 | 0.040 |
Why?
| | Forms and Records Control | 1 | 2019 | 20 | 0.040 |
Why?
| | Information Services | 1 | 2019 | 43 | 0.040 |
Why?
| | Pregnenolone | 1 | 2019 | 3 | 0.040 |
Why?
| | Gelatinases | 1 | 2019 | 6 | 0.040 |
Why?
| | Fibrinogen | 1 | 2020 | 180 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 134 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 332 | 0.040 |
Why?
| | Cystatin C | 1 | 2019 | 66 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3915 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2019 | 318 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2019 | 150 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2019 | 119 | 0.030 |
Why?
| | Flavonoids | 1 | 2019 | 85 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1751 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2933 | 0.030 |
Why?
| | Allografts | 1 | 2019 | 152 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 618 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2019 | 245 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2967 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 156 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 558 | 0.030 |
Why?
| | Metabolic Clearance Rate | 1 | 2015 | 115 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 924 | 0.030 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2014 | 25 | 0.030 |
Why?
| | Valsartan | 1 | 2014 | 32 | 0.030 |
Why?
| | Complement Hemolytic Activity Assay | 1 | 2013 | 2 | 0.030 |
Why?
| | Tetrazoles | 1 | 2014 | 50 | 0.030 |
Why?
| | Valine | 1 | 2014 | 83 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2013 | 27 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2014 | 80 | 0.030 |
Why?
| | Angiotensin II | 1 | 2014 | 102 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2026 | 6085 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3170 | 0.020 |
Why?
| | Veterans | 1 | 2025 | 1642 | 0.020 |
Why?
| | Leupeptins | 1 | 2012 | 13 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 419 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1049 | 0.020 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2012 | 32 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2012 | 41 | 0.020 |
Why?
| | Transcription Factor CHOP | 1 | 2012 | 32 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 88 | 0.020 |
Why?
| | Everolimus | 1 | 2012 | 112 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5922 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 6032 | 0.020 |
Why?
| | Pregnancy | 1 | 2005 | 7215 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 782 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 392 | 0.020 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2012 | 138 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 242 | 0.020 |
Why?
| | Multiprotein Complexes | 1 | 2012 | 172 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1378 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2010 | 61 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2013 | 401 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3118 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2010 | 152 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 456 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6464 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1857 | 0.020 |
Why?
| | Calcium | 1 | 2014 | 1191 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1708 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2014 | 2514 | 0.020 |
Why?
| | Proteins | 1 | 2012 | 1023 | 0.010 |
Why?
| | Aged | 1 | 2025 | 26215 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2012 | 2219 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 7133 | 0.010 |
Why?
|
|
Dixon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|